Evie Koslosky

Are you starting to see pharma invest more heavily in sort of lab in the loop and automation capabilities

what sort of demand are you seeing for your bioreactor sensors as people look to drive automation in their facilities?

Can you remind us what your exposure there is as a percentage of revenue

How much of this is incremental versus just kind of shifting geographies?

how much of the guidance raise in the acquired business is related to pricing?

can you talk to the decision to localize the manufacturing in flow cytometry in China

can you talk to the mid-teens growth in chemistry